Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year Low - What's Next?

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report)'s share price hit a new 52-week low during trading on Monday . The stock traded as low as $15.83 and last traded at $15.95, with a volume of 61229 shares changing hands. The stock had previously closed at $16.69.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Morgan Stanley assumed coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an "overweight" rating and a $35.00 target price for the company. Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set a "buy" rating and a $47.00 target price on the stock. HC Wainwright assumed coverage on shares of Bicara Therapeutics in a research note on Friday, December 6th. They issued a "buy" rating and a $42.00 price target for the company. TD Cowen started coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a "buy" rating for the company. Finally, Rodman & Renshaw began coverage on Bicara Therapeutics in a report on Tuesday, November 5th. They issued a "buy" rating and a $48.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $43.00.

Bicara Therapeutics Trading Down 6.6 %

The business has a fifty day simple moving average of $19.97.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Equities analysts anticipate that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Institutional Trading of Bicara Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. RA Capital Management L.P. purchased a new stake in shares of Bicara Therapeutics in the 3rd quarter worth about $177,169,000. FMR LLC bought a new stake in Bicara Therapeutics during the 3rd quarter valued at approximately $57,913,000. Braidwell LP purchased a new position in shares of Bicara Therapeutics during the 3rd quarter worth approximately $42,219,000. Janus Henderson Group PLC purchased a new position in shares of Bicara Therapeutics during the 3rd quarter worth approximately $30,329,000. Finally, Baker BROS. Advisors LP bought a new position in shares of Bicara Therapeutics in the 3rd quarter worth approximately $21,225,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.